4.7 Article

The small molecule IITR08027 restores the antibacterial activity of fluoroquinolones against multidrug-resistant Acinetobacter baumannii by efflux inhibition

Journal

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Volume 50, Issue 2, Pages 219-226

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijantimicag.2017.03.005

Keywords

Antibiotic resistance; Clinical strains; Combination therapy; Transporters

Funding

  1. Indian Council of Medical Research (ICMR) (New Delhi, India) [AMR/15/2011-ECD-I]
  2. ICMR
  3. Ministry of Human Resource Development, Government of India

Ask authors/readers for more resources

Efflux pumps are one of the major determinants of multiple drug resistance. In this study, AbeM, amultidrug efflux pump in Acinetobacter baumannii, was cloned into a multicopy plasmid (pUC18) and was transformed into an efflux-deficient mutant of Escherichia coli (KAM32). The elevated resistance profile of the recombinant E. coli for ciprofloxacin was utilised to screen a small-molecule library of 8000 molecules to identify IITR08027, a small molecule that is not inhibitory on its own but that could potentiate the activity of ciprofloxacin. When used in combination against A. baumannii, the molecule improves the killing efficiency of ciprofloxacin, extends its post-antibiotic effect and causes a decrease in frequency of resistant mutant selection with the antibiotic. Quinacrine-based fluorescence quenching and membrane depolarisation assays revealed that IITR08027 functions as a proton gradient inhibitor. This extends the activity of IITR08027 against other H+-driven efflux pumps such as AbeS. MTT assay against HeLa and HEK293 cells suggested that the molecule is non-toxic at its minimum effective concentration. We propose that, in combination with fluoroquinolones (ciprofloxacin and norfloxacin), IITR08027 may be effective against multidrug- resistant A. baumannii expressing AbeM or other efflux pumps that use the proton gradient as an efflux mechanism. (C) 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available